Metrics to compare | 338840 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship338840PeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −5.6x | −0.2x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | 7.3x | 1.2x | 2.6x | |
Price / LTM Sales | 39.8x | 8.3x | 2.7x | |
Upside (Analyst Target) | - | 107.5% | 69.6% | |
Fair Value Upside | Unlock | 20.5% | 11.7% | Unlock |
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.